Edesa Biotech

Company snapshot

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Edesa Biotech. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Edesa Biotech.

1. Jun 8, 2026 Clinical update

   SOC plus 15mg/kg EB05 IV — Phase 3

2. Jun 5, 2026 Clinical update

   EB01 Cream Placebo — Phase 2

3. Jun 5, 2026 Clinical update

   Cohort A: vilobelimab — Phase 2

4. May 23, 2026 Clinical update

   Cohort B: paridiprubart — Phase 2

5. May 23, 2026 Clinical update

   Cohort C: bevacizumab — Phase 2

View all clinical trial activity →

• What is Edesa Biotech?

  Edesa Biotech is a biotech organization headquartered in Markham, CA. It trades on NYSE under ticker EDSA. Primary therapeutic focus areas include Acute Respiratory Distress Syndrome (ARDS), Allergic Contact Dermatitis, COVID-19. NovaPharmaNews links 5 clinical program(s), 0 drug

• Is Edesa Biotech publicly traded?

  Yes. Edesa Biotech is listed with ticker EDSA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Edesa Biotech develop or market?

  We link 5 drug profile(s) where Edesa Biotech is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/edesa-biotech#company-drugs.

• What are the latest developments for Edesa Biotech?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Edesa Biotech focus on?

  Edesa Biotech focuses on Acute Respiratory Distress Syndrome (ARDS), Allergic Contact Dermatitis, COVID-19 based on our analysis of their pipeline programs and drug development activities.